Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2012
06/14/2012US20120148490 Anti-ngf compositions and use thereof
06/14/2012CA2830184A1 Ipn vaccine
06/14/2012CA2820837A1 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
06/14/2012CA2820796A1 Compositions and methods for vaccinating cattle
06/14/2012CA2820671A1 Tnf-.alpha. binding proteins
06/14/2012CA2820630A1 Dimeric molecular complexes with free cysteine residues and conjugates thereof
06/14/2012CA2820416A1 New pharmaceutical compositions
06/14/2012CA2820384A1 Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
06/14/2012CA2820382A1 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
06/14/2012CA2820134A1 Human monoclonal antibody
06/14/2012CA2819861A1 Novel modulators and methods of use
06/14/2012CA2819810A1 Granzyme b inhibitor compositions, methods and uses for promoting wound healing
06/14/2012CA2819554A1 Dosage and administration of bispecific scfv conjugates
06/14/2012CA2819366A1 Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
06/14/2012CA2819038A1 Humanized antibodies to liv-1 and use of same to treat cancer
06/14/2012CA2818669A1 Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
06/14/2012CA2818635A1 Antibodies selective for cells presenting erbb2 at high density
06/14/2012CA2818313A1 Anti ccr4 antibodies and uses thereof
06/13/2012EP2463369A1 Humanized anti-amyloid-b oligomer antibody
06/13/2012EP2463368A1 Humanized anti-amyloid-b oligomer antibody
06/13/2012EP2463299A2 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
06/13/2012EP2462950A1 Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
06/13/2012EP2462949A2 Meningococcal vaccine formulations
06/13/2012EP2462948A1 Bacterial virulence factors and uses thereof
06/13/2012EP2462947A1 PRAME derived peptides and immunogenic compositions comprising these
06/13/2012EP2462930A1 Induction of an immune response against dengue virus using prime-boost approach
06/13/2012EP2462929A1 Sheet-form preparation and method for producing the same
06/13/2012EP2462928A1 Sheet-form preparation and method for producing the same
06/13/2012EP2462162A1 Antibodies that specifically bind to a beta oligomers and use thereof
06/13/2012EP2462161A1 Antibodies that specifically bind to a beta oligomers and use thereof
06/13/2012EP2462160A1 Porphyromonas gingivalis polypeptides
06/13/2012EP2462159A1 Immunogenic composition comprising variants of staphylococcal clumping factor a
06/13/2012EP2461870A1 Therapeutic compositions and methods
06/13/2012EP2461829A2 Novel proteins
06/13/2012EP2461828A1 Programming of cells for tolerogenic therapies
06/13/2012EP2461827A2 Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector
06/13/2012EP2461826A2 Composition for treating hbv infection
06/13/2012EP2461825A2 Anti-rsv immunogens and methods of immunization
06/13/2012EP2461824A1 Immunogenic composition comprising antigenic s. aureus proteins
06/13/2012EP2461823A1 A vaccine directed against porcine pleuropneumonia and a method to obtain such a vaccine
06/13/2012EP2461822A2 Polymer particles and uses thereof
06/13/2012EP2461813A1 Compositions and methods for inducing apoptosis in prostate cancer cells
06/13/2012EP2461677A1 Concentrated polypeptide formulations with reduced viscosity
06/13/2012EP1947110B1 Intranasal vaccine for use against disease caused by enterotoxigenic escherichia coli
06/13/2012EP1888107B1 Novel vaccine formulations
06/13/2012EP1848794B1 Compositions comprising dehydrated micro-organisms, method for preparing same, and uses thereof
06/13/2012EP1812058B1 Chlamydia trachomatis antigens for vaccine and diagnostic use
06/13/2012EP1768995B1 Preparation of protective antigen from bacillus anthracis
06/13/2012EP1745076B1 Antibodies specific for glycoprotein vi and methods of producing these antibodies
06/13/2012EP1720571B1 Method of treating hemolytic disease
06/13/2012EP1699460B1 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
06/13/2012EP1663302B1 Method for vaccination of poultry by bacteriophage lysate
06/13/2012EP1613273B1 Recombinant il-9 antibodies and uses thereof
06/13/2012EP1609804B1 Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme
06/13/2012EP1587837B1 Epitope sequences for prostate cancer diagnosis and treatment
06/13/2012EP1587542B1 Use of anti-cd100 antibodies
06/13/2012EP1585542B1 Immunogenic compositions containing phospholipid
06/13/2012EP1554311B1 Humanized antibodies that recognize beta amyloid peptide
06/13/2012EP1495053B1 Angiopoietin-2 and angiopoietin-1 specific binding agents
06/13/2012EP1490110B1 Anti-alpha v beta 6 antibodies
06/13/2012EP1480666B1 Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
06/13/2012EP1459070B1 Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers
06/13/2012EP1447095B1 Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
06/13/2012EP1414471B1 Therapeutic agents comprising pro-apoptotic proteins
06/13/2012EP1379535B1 Expression vectors able to elicit improved immune response and methods of using same
06/13/2012EP1355666B1 Use of repulsive guidance molecule (RGM) and its modulators
06/13/2012EP1297017B1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
06/13/2012EP1296705B1 Amyloid Beta oligomers for use in treatment, alleviation or prevention of Alzheimer's Disease
06/13/2012EP1235594B1 Inhibition of secretion from non-neuronal cells
06/13/2012EP0904288B1 Vaccine comprising the pathogenic escherichia coli associated protein espa
06/13/2012EP0451216B2 Humanized immunoglobulins and their production and use
06/13/2012CN1835976B Aglycosyl anti- CD154 (CD 40 ligand) antibodies and uses thereof
06/13/2012CN1688337B Use of digoxin immune FAB (ovine) for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients
06/13/2012CN102498130A Induction of P53 expression by neutralization of neuropilin-2 for the treatment of cancers
06/13/2012CN102498129A Inhibition of tumor metastasis using bv8- or g-csf-antagonists
06/13/2012CN102497885A Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
06/13/2012CN102497880A Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
06/13/2012CN102497879A Single-time vaccines
06/13/2012CN102497875A Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions
06/13/2012CN102497868A Mixture of non-digestible oligosaccharides for stimulating the immune system
06/13/2012CN102492661A Preparation method and application of immunization preparation for controlling novel duck reovirus
06/13/2012CN102492039A Fully humanized antihuman HER2 monoclonal antibody
06/13/2012CN102492038A Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
06/13/2012CN102492023A PLAC1 anti-tumour CTL epitope peptide and application thereof
06/13/2012CN102488899A Preparation method and application of yolk immunoglobulin sustained-release preparation
06/13/2012CN102488898A Carious tooth vaccine and preparation method
06/13/2012CN102488897A Preparation method for lyophilized immunologic adjuvant
06/13/2012CN102488896A Preparation method for anti-tumor medicine and adjuvant thereof
06/13/2012CN102488895A Porcine circovirus, porcine parvovirus and porcine reproductive and respiratory syndrome virus triple virus-like particle vaccine and its preparation method
06/13/2012CN102488894A Fox encephalitis live vaccine and preparation method thereof
06/13/2012CN102488893A Duck hemorrhagic oophoritis inactivated vaccine production method by using cell line and product thereof
06/13/2012CN102180962B Tetraodon nigroviridis interferon IFNgamma1 and preparation method and application thereof
06/13/2012CN102180961B Black-blue spotted puffer fish interferon IFN gamma 2 and preparation method and application thereof
06/13/2012CN101993888B Method for producing and recombining main allergic protein Hum j 3 of Humulus scandens by induced secretion expression
06/13/2012CN101816790B Spray for treating radioactive xerostomia and preparation method thereof
06/13/2012CN101648011B Tumor targeting recombinant DNA vaccine, preparation method thereof and application thereof
06/13/2012CN101641117B Pharmaceutical composition
06/13/2012CN101607983B Encephalitis B virus PrM/M protein B cell antigen epitope polypeptide and applications
06/13/2012CN101570574B Anti-I type Shiga toxin IgY antibody as well as preparation method and use thereof
06/13/2012CN101376027B Recombined newcastle disease virus LaSota attenuated vaccine strain for expressing avian influenza virus H9 subtype HA protein
1 ... 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 ... 1823